Source comparison
NAD+ Alternative to NR Supplements: Direct Comparison
NR (Nicotinamide Riboside) Feeds NAD+ salvage pathway via NRK→NMNAT conversion 300–1000mg daily oral 15–25% reaches tissues intact (rest converts to NAM in gut/liver) Multiple human RCTs showing NAD+ elevation; mixed results on functional outcomes (exercise, c
This comparison does not assign a generated winner or score.
- NR (Nicotinamide Riboside)
- Feeds NAD+ salvage pathway via NRK→NMNAT conversion
- 300–1000mg daily oral
- 15–25% reaches tissues intact (rest converts to NAM in gut/liver)
- Multiple human RCTs showing NAD+ elevation; mixed results on functional outcomes (exercise, cognition)
- Proven NAD+ booster but outcome data inconsistent. Works if salvage pathway is functional
- MOTS-c Peptide
- Activates AMPK directly; increases mitochondrial biogenesis independent of NAD+
- 5–15mg subcutaneous 2–3×/week
- ~90% subcutaneous bioavailability (bypasses gut metabolism)
- Phase 1 human trial showed improved insulin sensitivity; rodent data robust for longevity/exercise
- Targets energy dysfunction upstream of NAD+. Requires injection, limited human trial volume
- NMN (Nicotinamide Mononucleotide)
- One step closer to NAD+ than NR (skips NRK step)
- 250–500mg daily oral
- Likely similar to NR (gut metabolism reduces intact absorption)
- Human trials emerging; rodent data shows faster NAD+ elevation vs NR
- Theoretical advantage over NR but human evidence still limited. Cost typically higher
- MitoQ (Mitochondrial Antioxidant)
- Delivers CoQ10 directly to mitochondrial matrix via TPP+ cation
- 10–20mg daily oral
- Mitochondrial accumulation 100–800× higher than unmodified CoQ10
- Human trials in heart failure, kidney disease show reduced oxidative stress; no longevity RCTs
- Reduces oxidative damage but doesn't increase energy production. Complementary, not equivalent